Full-Time
Posted on 7/17/2025
At-home fertility diagnostics and non-invasive device
$190k - $270k/yr
Burlingame, CA, USA
In Person
| , , |
Neptune Medical develops devices and tests to address male infertility. Its two main products are Pro-Test, an at-home diagnostic kit that lets individuals test fertility parameters from home, and Neptune, a non-invasive device designed to improve sperm quality. Pro-Test provides a convenient way to assess fertility without clinic visits, while Neptune uses a proprietary, non-invasive method to enhance key sperm metrics and is intended for home use alongside clinical fertility treatment. The company serves both clinics (B2B) and individual consumers (B2C) and markets its products to help diagnose and treat male infertility, a factor in about half of all infertility cases. Neptune Medical differentiates itself by offering integrated, consumer-accessible diagnostics and treatment tools, backed by grant funding and participation in precision medicine programs, aiming to make diagnosis and treatment more private, accessible, and effective.
Company Size
1-10
Company Stage
Series D
Total Funding
$97M
Headquarters
Burlingame, California
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
401(k) Company Match
Company Equity
Listen to this articleSwiss-Mile raised $22M in August 2024 for its wheeled quadruped. Fifty producers of robots and robotics enabling technologies received funding in August 2024, pulling in a total of approximately $1 billion. This figure is on par with the $1.2 billion average The Robot Report has tracked each of the previous 12 months. Investment targeted to robotics companies for the first eight months of 2024 equals about $10.86 billion. You can follow The Robot Report‘s investment section here. The largest investments in August were secured by developers of autonomous driving technologies
Neptune Medical announces $97 million in Series D financing, along with the spinout of its Jupiter Endovascular subsidiary.